While dopamine agonists are indicated in cases of prolactin co-secretion by true somatomammotroph tumors or mixed adenomas in order to control the prolactin excess, its merit as co-medication for lowering the GH output by the adenoma appears mainly to be in patients with IGF-I levels not exceeding twice the upper limit of normal (22, 23). Here, IGF1 is linked to adenoma.